Compare Davita Inc (DVA) vs S&P500 ETF (SPY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs S&P500 ETF — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while S&P500 ETF trades at $777.16 (market cap $821.54B). The key difference: S&P500 ETF is far larger — about 72.8× Davita Inc's market cap, and S&P500 ETF is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and S&P500 ETF for 205 Days on average.
| DVA | SPY | |
|---|---|---|
Market Cap | $11.29B | $821.54B |
Volume | 582,204 | 40,070,358 |
Sector | Health | — |
52-Week High | $240.96 | $779.14 |
52-Week Low | $103.87 | $631.99 |
Typical Hold Time | 113 Days | 205 Days |
Enterprise Value | $24.01B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
SPY, the SPDR S&P 500 ETF, trades at $777.26, down 0.24% on the day, with a bullish technical signal from moving averages but a neutral reading from oscillators. The ETF is near its pivot point of $776, with immediate resistance at $779. Recent news highlights mixed sentiment, with some articles pointing to strong corporate earnings growth in 2026 but expected deceleration in 2027, while others discuss defensive positioning and valuation concerns.
The outlook for SPY is cautiously optimistic, supported by bullish technical trends and robust earnings growth projections for 2026. Key risks include potential profit growth slowdown in 2027, elevated market valuations, and macroeconomic headwinds such as rising Treasury yields. Investors should weigh the ETF's broad market exposure against these factors for long-term positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →
